LEXARIA BIOSCIENCE CORP. Proceeds from Sale of Held-to-maturity Securities
LEXARIA BIOSCIENCE CORP. (LEXX) reported Proceeds from Sale of Held-to-maturity Securities of $6.50 million for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. proceeds from sale of held-to-maturity securities for the quarter ending 2026-05-31 was $0.00, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. proceeds from sale of held-to-maturity securities for the quarter ending 2026-02-28 was $3.10M.
- LEXARIA BIOSCIENCE CORP. proceeds from sale of held-to-maturity securities for the quarter ending 2025-11-30 was $3.40M.
- LEXARIA BIOSCIENCE CORP. proceeds from sale of held-to-maturity securities for the quarter ending 2025-08-31 was $0.00.
- LEXARIA BIOSCIENCE CORP. proceeds from sale of held-to-maturity securities for fiscal 2025 was $6.00M.
| Period end | Proceeds from Sale of Held-to-maturity Securities 3 month | Proceeds from Sale of Held-to-maturity Securities 6 month | Proceeds from Sale of Held-to-maturity Securities 9 month | Proceeds from Sale of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $3.10M derived: sum of 2 quarters · filed 2026-07-13 | $6.50M 10-Q · filed 2026-07-13 | $6.50M derived: sum of 4 quarters · filed 2026-07-13 |
| 2026-02-28 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $6.50M 10-Q · filed 2026-04-13 | $6.50M derived: sum of 3 quarters · filed 2026-04-13 | $8.10M derived: sum of 4 quarters · filed 2026-04-13 |
| 2025-11-30 | $3.40M 10-Q · filed 2026-01-13 | $3.40M derived: sum of 2 quarters · filed 2026-01-13 | $5.00M derived: sum of 3 quarters · filed 2026-01-13 | |
| 2025-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $1.60M derived: sum of 2 quarters · filed 2025-11-28 | $6.00M 10-K · filed 2025-11-28 | |
| 2025-05-31 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-07-14 | $6.00M 10-Q · filed 2025-07-14 | ||
| 2025-02-28 | $4.40M 10-Q · filed 2025-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |